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CI1.05-1.89; p= 0.024). MI were slightly less likely to schedule DFE vs. UC (38% vs. 
42%, RR0.90; CI0.66-1.22; p= NSS) and attend DFE (32% vs. 36%; RR0.90; CI 0.63-1.28; 
p= NSS). The total cost of TI was $603.98 or $5.03/participant and the cost/follow-up 
DFE was $26.05. Sensitivity analyses revealed that the cost/follow-up can be greatly 
reduced but remains additional vs. UC ($2.76 if $0.25/call, $11.13 if $1/call; $22.29 
if $2/call). ConClusions: Personal phone assistance in scheduling DFE follow-
up assistance is more effective but also more costly. Follow-up research has been 
initiated to determine whether automated phone reminders can achieve similar 
effectiveness at a lower cost.
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objeCtives: Compare health care resource utilization and costs of Cushing disease 
(CD) cases to CD-free controls. Methods: A retrospective matched-cohort study 
design was used to analyze the administrative claims of commercial health plan 
enrollees with evidence of CD from 2007-2011. CD cases were matched 1:3 to CD-free 
controls by age, sex, region, and index year. CD cases were identified using a Cushing 
syndrome diagnosis code (ICD-9: 255.0) and codes for a CD-related diagnosis or 
procedure (e.g., pituitary neoplasm or hypophysectomy). CD cases were observed for 
≥ 6 months after their first CD-related claim. Controls were observed starting in the 
same index year. Per-patient-per-month (PPPM) counts and costs of all-cause health 
care resource utilization were compared descriptively. Costs were CPI-adjusted to 
2011 dollars and included health plan- and patient-paid amounts. Results: Among 
the 885 selected CD cases and 2,655 matched controls, the mean (SD) age was 42 
(14) years and 75% were female. Median follow-up was 2.4 years for cases and 1.5 
years for controls. Compared to controls, cases had a higher proportion of inpa-
tient admissions (50% vs. 11%; p< 0.001), emergency department visits (61% vs. 20%; 
p< 0.001), and outpatient visits (95% vs. 63%; p< 0.001). Average monthly counts of 
utilization for cases were 2-4 times higher than controls: ambulatory visits (2.5 vs. 
0.9; p< 0.001), ED visits (0.1 vs. 0.04; p< 0.001), and inpatient admissions (0.03 vs. 0.01; 
p< 0.001). Average PPPM total all-cause costs were also higher for cases than controls 
($3,224 vs. $486; p< 0.001), and were largely driven by medical costs ($2,790 vs. $382; 
p< 0.001). Average PPPM pharmacy costs were 4 times higher for cases than controls 
($434 vs. $104; p< 0.001). ConClusions: In this study, high health care resource 
utilization and costs were identified for CD cases compared to CD-free controls. In 
addition to CD treatment costs, differences included the costs of diagnosing and 
treating the multiple comorbidities often observed in CD patients.
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objeCtives: In Ukraine COPD is significant medical and socio-economic prob-
lem. The aim of this study was to assess and compare the 2013 annual exacerba-
tion-related direct costs in COPD stages subpopulations. Methods: Costs were 
assessed with State Budget perspective. Inpatient costs included service costs and 
costs for diagnostic procedures. Outpatient costs included physician visits and 
spirometry costs. Epidemiological and cost data were obtained from the appro-
priate 2012-2020 model. Data about the proportions of I-IV COPD were obtained 
from Ukrainian study: I, II, III and IV was 20%, 44%, 29% and 7%, respectively. Data 
about annual exacerbations and hospitalizations rates were obtained from GOLD 
2013: I: no data; II:0.7-0.9 and 0.11-0.2; III:1.1-1.3 and 0.25-0.3; VI:1.2-2.0 and 0.4-0.54, 
respectively. We made an assumption that the annual number of exacerbation led 
to outpatient visits was the difference between total exacerbations rate and hos-
pitalization rate (2 outpatient visits per exacerbation). Costs were considered in 
minimal and maximal exacerbation rates scenarios and were calculated per sub-
population and per patient. 11% inflation rate, 17.6% social-tax and 17% VAT were 
applied. Exchange rate 1USD= 7.99UAH on 30.12.2013. Results: In 2013 number 
of COPD patients in Ukraine was 581,598. Number of patients with I, II, III and IV 
stages could amount 116,320; 255,903; 168,663 and 40,712, respectively. Minimal-
maximal annual inpatient costs in II, III and IV COPD subpopulations could amount 
$6,310,192.66-$11,473,077.56 ($25.00-$45.00 per patient), $9,452,232.30-$11,342,678.76 
($56.04-$67.25 per patient) and $3,650,538.95-$4,928,227.58 ($90.00-$121.00 per 
patient), respectively. Minimal-maximal annual outpatient costs in II, III and IV 
subpopulations could amount $859,721.71-$1,355,712.42 ($3.36-$5.30 per patient), 
$1,253,374.56-$1,645,054.12 ($7.43-$9.75 per patient) and $889,441.63-$2,156,222.13 
($21.85-$52.96 per patient), respectively. ConClusions: Total direct costs were 
largest in COPD III patients, but per-patient direct costs were largest in COPD IV. So, 
in case of COPD-related costs assessment the stratification of patients by airflow 
limitation and exacerbations rates should be taken in account.
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objeCtives: Estimate the cost of treating hypoglycemic events in patients with 
type 2 diabetes mellitus (DM2), in the Mexican public health care system using 
data from two databases and to compare these costs according to hypoglycemic 
event severity. Methods: A Cost Analysis was developed to estimate the economic 
impact of treating hypoglycemic events. Definition of hypoglycemia was according 
with the published by Jonsson and colleagues1: Mild, Moderate and Severe. The use 
of resources was validated with an expert panel of specialists from the public health 
system. Only direct costs were used in this analysis. Estimates were obtained from 
I2= 18%]. Having an end-of-life, hospice, or palliative care facility in the nursing home 
increased the likelihood of dying in a nursing home vs. hospital (OR 7.79 [2.22–27.31], 
4 studies, I2= 98%). ConClusions: Availability of services influences the site of 
death. For patients preferring death at home, the presence of a multidisciplinary 
home care team is one of the factors that can support home death.
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objeCtives: This study was conducted to evaluate the appropriate use of medi-
cines among the hospitalized patients with renal impairment. Methods: Study 
Design:The study was a retrospective study in which medication charts (prescription 
and laboratory reports) of patients were used to evaluate appropriate use of medi-
cines. Setting: Data was collected from nephrology departments of selected hospitals 
of Gujarat, Bahawalpur and Lahore. Main outcome measure: Percentage of prescrip-
tions containing contraindicated drugs, percentage of prescriptions containing 
drugs prescribed without adjusting their doses, percentage of prescriptions contain-
ing drug-drug interactions and percentage of drugs prescribed without specifying 
any dose. Results: About 500 prescriptions of patients (male and female) with 
moderate and severe renal impairment were collected and evaluated. According 
to this study, contraindicated drugs were observed in 30.8% prescriptions, drugs 
prescribed without dose adjustment were found in 51% prescriptions, drug-drug 
interactions were observed in 63.6% prescriptions and drugs prescribed without 
any specific dosage regimen in 4.8% prescriptions. At least one drug interaction was 
found in each prescription (median = 1, inter quartile range = 1-6). ConClusions: 
This study showed the negligence of health care providers especially physicians 
and nephrologists. The study provided evidence that either physicians do not take 
notice of patient’s renal function while prescribing or are incompetent enough to 
take such measures. Interventions are required to improve the prescribing quality 
and prescribers’ behaviors that will ultimately improve the quality of care.
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objeCtives: The Post-Licensure Rapid Immunization Safety Monitoring (PRISM) pro-
gram was created in response to the need of the U.S. Food and Drug Administration 
(FDA) to monitor the safety of H1N1influenza vaccine. Later PRISM was incorporated 
into the FDA’s Mini-Sentinel Initiative to evaluate the safety of other vaccines. We 
describe the distributed data structure used in this system. Methods: PRISM uses 
a distributed data method whereby claims data processed through 3 health insur-
ance companies, “Data Partners,” are organized into a standardized common data 
model (CDM). Data in this standard format are refreshed on a quarterly basis and 
stored by the Data Partners. Mini-Sentinel programs are run on these data to extract 
aggregate data for analysis. The data in the CDM are augmented by linking to eight 
state and city Immunization Information Systems (IIS) to obtain additional vaccine 
exposure data. Results: The CDM includes 110 million lives, 2.6 billion dispensing, 
and 3.1 billion health care encounters from 2004-2012 from the three Data Partners, 
representing three major health insurance companies. The vaccine data from the 
state IIS improve the completeness of vaccine information for individuals. In 2012, 
unrestricted (including states even if they did not contribute data) analysis showed 
that IIS contributed an additional 5-9% of vaccine administration data. In the chart 
validation assessing the risk of intussusception following rotavirus vaccination, 
it was identified that 46% (124/267) of cases identified by the electronic algorithm 
were true intussusception cases. Reports on one vaccine safety assessment has 
been completed. ConClusions: Vaccines are an essential component to maintain 
public health. The benefits of the PRISM system include the large pooled population, 
enhanced ability to capture data from alternative sources, and ability to evaluate the 
potential risks of rare adverse events; the distributed data model ensures patient 
confidentiality. Validation by chart review adds precision to the evaluations.
HEaLtH SErvicES – cost Studies
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objeCtives: To compare effectiveness and costs of personal reminder approaches 
(mailed vs. phone) to improve dilated fundus examination (DFE) follow-up adher-
ence in patients with diabetes. Methods: In a prospective trial, 356 diabetics due 
for DFE were randomly assigned to usual care (UC; reference case), mailed interven-
tion (MI), or telephone intervention (TI). UC (n= 119) received a standard form letter. 
MI (n= 117) received a personalized letter encouraging scheduling of eye examina-
tion with an educational brochure about diabetic eye disease. TI (n= 120) received 
personal calls (up to 3 attempts) to schedule a follow-up with standard form letter. 
The primary outcome was DFE within 90 days of suggested return. Costs ($US 2013) 
included time costs (staff time in preparing letters, conducting calls, and documen-
tation converted to dollars using wages + benefit costs), phone charges, supplies, 
and postage. Since TI dominated MI, univariate sensitivity analysis examined the 
impact of reducing phone costs. Results: Participants were mostly female (66%) 
and African-American (70%) with a mean age of 61 years. TI were more likely to 
schedule DFE (65% vs. 42%; RR1.54; CI1.20-1.96; p< 0.001) vs. UC. DFE within 90 days 
of suggested return in TI was also significantly higher than UC (51% vs. 36%, RR1.41; 
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individuals. The study population was identified through a data warehouse (DENALI), 
which matches with a probabilistic linkage demographic, clinical and economic data 
of different Healthcare Administrative databases. Using DENALI we detected all sub-
jects who were hospitalized for stroke (ICD-9 CM: 430.xx-438.xx) during the period 
2000–2010. The first hospital admission date was used as index date. We estimated 
incidence, mortality and health care costs (hospitalizations, drugs and outpatient 
examinations/visits) per patient-year from the National Health Service’s perspec-
tive. Results: During the study period, around 530,000 subjects (48.3% male) expe-
rienced at least one hospital admission for stroke, corresponding to 5.2 cases on 1,000 
Lombardy inhabitants per year. Subjects had a mean (±SD) age of 74.0 (±13.2) years. 
Ischemic stroke represented the most frequent diagnosis (36.8%) followed by transient 
ischemic attack (TIA, 11.2%) and hemorrhagic stroke (9.0%). The overall mortality rate 
(x100 person-years) was 11.7, with a significant worst survival for hemorrhagic (16.7) 
and ischemic (9.1) diagnosis with respect to TIA (7.8). The average cost during the 
index year was around 6,000€ /patient-year, 10,000€ /patient-year and 20,000€ /patient-
year for TIA, ischemic and hemorrhagic stroke, respectively. For these diagnoses the 
main cost driver was represented by hospitalizations, accounting for 78%, 87% and 
94%. ConClusions: Stroke is a burdensome condition with a high mortality dis-
abilities and costs, indicating the primary importance in monitoring the developing 
of the disease from the NHS’s perspective. Administrative database analysis shows to 
be an efficient tool to accurately estimate the burden of stroke diagnoses.
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objeCtives: Long-term health and economic consequences of diabetes mellitus 
are of significant importance to health policy makers to identify the most effi-
cient interventions for disease managements. However, existing data are mainly 
from simulation models instead of “real-world” data. The objective of this study 
was to longitudinally evaluate the changes of prevalence of diabetic complica-
tions and associated health care cost in a nationally-representative longitudinal 
diabetic cohort. Methods: We used the 2000-2011 Taiwan’s Longitudinal Health 
Insurance Database (LHID) to conduct a population-based, cohort study of 136,372 
type 2 diabetic patients. Diabetic complications of each patient were calculated 
annually after the cohort entry by the adapted Diabetes Complications Severity 
Index (aDCSI) score (sum of diabetic complication with severity levels, range 0-13) 
using diagnostic codes recorded in the LHID. Study subjects were further catego-
rized into six subgroups according to their aDCSI score (0, 1, 2, 3, 4, 5+) at cohort 
entry. Health care utilizations (including outpatient and inpatient visits) as well as 
direct medical costs for the six subgroups were estimated annually using patient-
level data from the LHID. Results: We found the severity of diabetic complications 
increased over time, especially for patients with aDCSI score of 2 and above at cohort 
entry (at 10-years of follow-up: aDCSI= 0 (cohort entry), 2.37; aDCSI= 1; 3.59; aDCSI= 2; 
4.60; aDCSI= 3; 5.14; aDCSI= 4; 5.96). There were significant differences in health 
care utilizations and associated medical costs among patients stratified by aDCSI 
scores (e.g. at 1 year after cohort entry, mean counts of inpatient visits: 0.14 vs. 1.81 
for aDCSI= 0 vs.5+). Relatively high health care utilizations and associated medical 
costs in the first year of cohort entry were observed for patients with aDCSI score 
of 4 and above at cohort entry ConClusions: We provide significant evidence for 
longitudinal changes in diabetic complications and associated health care utiliza-
tion and medical costs among diabetic patients.
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objeCtives: To estimate the Brazilian supplementary health system costs of acute 
coronary syndrome (ACS), considering direct costs under the private payer perspec-
tive. Methods: Retrospective transactional-level data collection about hospitaliza-
tion costs based on claims data from a private payer perspective. Data were collected 
based on patients´ admission International Code of Disease version 10 (ICD-10) of 
Myocardial Infarction (MI) or unstable angina (UA). Index hospitalization direct costs 
were retrieved from private databases and a one year follow up was performed to 
evaluate rate of readmission and its associated costs. Patients were divided in 4 
main groups based on treatment adopted at index hospitalization: clinical treat-
ment (CT), angioplasty with stent placement (AngSt), Coronary Artery Bypass Graft 
(CABG) and Angioplasty without stent placement (Ang). Results: 2,803 hospitali-
zations were analyzed.Average age was 61 years old and 77% were men. We found 
that 85,44% underwent AngSt, 7,46% CABG, 5,6% Ang and 1,5% CT. Death rates were 
1,63%, 6,22%, 5,73%, 4,76% for AngSt, CABG, Ang and CT respectively. The average 
hospitalization costs for each group was: US$ 17,656 for AngSt, US$ 20,762 for CABG, 
US$ 15,638 for Ang and US$ 9,331 for CT. Readmission after index hospitalization 
were: 7,56%, 1,91%, 5,1% and 21,43% for AngSt, CABG, Ang and CT respectively. And 
the associated cost were US$ 13,986, US$ 12,643, US$13,000 and US$ 12,945 respec-
tively. ConClusions: AngSt is the most common treatment adopted for managing 
ACS with an average cost of US$ 17,656, followed by CABG with an average cost of 
US$ 20,762. ACS has an important economic burden for private payers that can be 
prevented. Mostly important, rehospitalization after an ACS episodemust be avoided 
due its high economic impact.
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two different sources: the unitary cost published by the Mexican Social Security 
Institute (IMSS) and the recovery cost of the General Hospital of Mexico (both with 
2013 costs). Results: The cost of treating hypoglycemic events varies according 
to severity. The main difference between the severities of hypoglycemia was in 
the hospitalization days; in mild hypoglycemia there was no hospitalization, but 
in a severe hypoglycemia it was considered 1.46 (SD±0.77) days in urgency and 
3.77(SD±1.01) days in hospitalization. In the case of the IMSS, the cost of treating a 
hypoglycemic event was US$997.81, US$1,901.78 and US$2,709.4 for mild, moder-
ate and severe hypoglycemia, while for the General Hospital case the costs were 
US$457.69, US$677.88 and US$902.22, respectively. ConClusions: The high cost 
of providing medical care to patients with hypoglycemia and its complications 
represents an economic burden to the Mexican public health care system. Currently, 
effective therapies exist for the treatment of DM2 which have a lower risk of causing 
hypoglycemic events, and consequently greater control of glucose levels. From a 
public health perspective, the use of agents with greater safety and effectiveness in 
the treatment of DM2 could avoid the high costs of treating hypoglycemic events.
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objeCtives: Although breast cancer occurs primarily among women over age 50 
years, each year more than 10,000 cases are diagnosed among women aged 18-44 
years. To date, no study has specifically quantified the economic burden of breast 
cancer in this age group in the United States. This study is the first to estimate work 
and home productivity losses due to breast cancer among younger women aged 
18-44 years. Methods: We used a two-part regression model and data from the 
2000–2010 National Health Interview Survey to estimate the number of work and 
home productivity days missed due to breast cancer, adjusted for socioeconomic 
characteristics and comorbidities. We compared our estimates for younger women 
with those of older women aged 45-64 years. Results: Per capita, younger women 
with breast cancer had annual losses of $2,293 (95% confidence interval [CI]: $1,069-
$3,518) from missed work and $288 (95% CI: $105-$471) from missed home produc-
tivity. Younger women too sick to work had annual breast cancer-attributable work 
loss costs of $365 per person (95% CI: $208-$522). In total, breast cancer-attributable 
morbidity costs for younger women were $274 million (95% CI: $128-$420 million) 
for work loss among the employed, $46 million (95% CI: $17-$75 million) for home 
productivity, and $10 million (95% CI: $6-$15 million) for work loss among women 
too sick to work. Older women with breast cancer had lower per capita work loss 
costs but higher total morbidity costs. ConClusions: Younger women with breast 
cancer face significant work and home productivity losses. These results underscore 
the importance of continued efforts by the public health community to support the 
unique needs of younger breast cancer survivors and promote prevention efforts 
throughout the lifespan.
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objeCtives: To determine and compare: 1) the incremental total costs (direct and 
indirect) for children (age 3-17 years) with and without ADHD; and 2) differences in 
the incremental direct costs for children with and without ADHD with respect to age 
groups (infants, 0-5; children, 6-11; and adolescents, 12-17 years); while controlling 
for covariates. Methods: The 2011 Medical Expenditure Panel Survey (MEPS) was 
the data source for the study. The sample consists of all children (age 0-17 years) 
with a diagnosis of ADHD (ICD9-code= 314) (Group-I) and without a diagnosis of 
ADHD (Group-II). The incremental total cost of ADHD comprised of direct expendi-
tures (prescribed medications, inpatient, ambulatory, and emergency department 
care), and the indirect costs (parents’ loss of productivity due to absence from school 
by children). A two-part model with logistic regression and a generalized linear 
model was used to estimate the incremental costs of ADHD while controlling for age, 
gender, race, Charlson co-morbidity index, family income, health insurance, usual 
source of care, area, and region. SAS 9.3 and STATA 12.0 were used for statistical 
analyses. Results: 2011 MEPS included 9838 children (age 0-17 years), of whom 
494 (5.02%) children had a diagnosis of ADHD. Group-I was 2.74 times more likely 
(CI= 1.62 to 4.62, p < 0.001) than Group-II to have an expenditure of at least $1, and, 
among children with positive expenditures, Group-I had 33% higher expenditures 
than Group-II (p = 0.001) after controlling for covariates. The incremental direct cost 
of ADHD was higher among adolescents than infants or children [$683 (p= 0.011) vs. 
$494 (p= 0.018) vs. $458 (p = 0.013)], after controlling for covariates. ConClusions: 
Children with ADHD have significantly higher costs than children without ADHD. 
Further research is needed to substantiate the high expenditures associated with 
ADHD.
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objeCtives: Stroke is a sudden loss of brain function due to inadequate blood flow 
with high impact on health status and severe prognosis. The objective of this analy-
sis was to assess incidence, mortality and economic burden of stroke from a large 
population based-study. Methods: Lombardy Region includes around 9.9 million 
